The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated×6•Originally published 5 May 2026•Updated 7 May 2026•

1 min read

Q1 2026 Earnings: Vertex and IQVIA Beat Estimates as HII Reports Mixed Results

Key Facts

1The company reported an EPS of $4.47, exceeding forecasts for the first quarter of 2026.

2Revenue reached $2.99 billion, which missed analyst projections.

28 days ago

Version History

1 additional source confirmed this story

Version 628 days ago

What changed: Added earnings reporting updates for Mirum Pharmaceuticals, LifeVantage, and LifeMD to the existing healthcare sector coverage.

Version 528 days ago

What changed: Added specific EPS figures for Vertex, valuation metrics (P/E and P/S ratios), and details regarding pipeline competition and market uptake challenges.

Version 428 days ago

What changed: Added specific earnings call details for Ultragenyx (RARE) and negative earnings expectations for ARS Pharmaceuticals (SPRY).

Version 329 days ago

What changed: Added earnings call and financial result information for Rhythm Pharmaceuticals, Willis Lease Finance Corporation, and Frontier Group Holdings to the existing coverage.

Version 229 days ago

What changed: The story was updated to include Q1 earnings results for IQVIA, Huntington Ingalls Industries, and Pediatrix Medical Group, broadening the scope beyond the initial Vertex report.

Version 130 days ago

What changed: Updated headline and body to correct the revenue status from a 'miss' to 7.8% year-over-year growth, adding specific details on cystic fibrosis sales, market cap, and stock price.

The healthcare sector saw strong Q1 2026 results, led by Vertex Pharmaceuticals reporting an EPS of $4.02 and 7.8% revenue growth. In recent updates, Mirum Pharmaceuticals (MIRM) and LifeMD (LFMD) released their Q1 2026 earnings reports, providing further clarity on sector performance. Additionally, LifeVantage (LFVN) announced its Q3 2026 financial results, adding to the wave of corporate disclosures. These updates follow IQVIA Holdings exceeding forecasts due to AI demand and Huntington Ingalls Industries (HII) posting an EPS of $3.79. Market sentiment remains focused on upcoming reports, including ARS Pharmaceuticals, where earnings declines are anticipated.